to discuss the current treatment landscape and the potential of Lexicon's recently approved dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin) in patients with heart failure
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the data from the SCORED and SOLOIST-WHF phase 3 clinical trials on Lexicon's recently approved dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin).
Ticker(s): LXRXWho's the expert?
Institution: Mercy Health Services
- Director of Echocardiography and board certified cardiologist with Mercy Health
- Currently manages 300 patients with heart failure
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
